Cargando…
Tissue Biomarkers for Prostate Cancer Radiation Therapy
Prostate cancer is the most common cancer and second leading cause of cancer deaths among men in the United States. Most men have localized disease diagnosed following an elevated serum prostate specific antigen test for cancer screening purposes. Standard treatment options consist of surgery or def...
Autores principales: | Tran, PT, Hales, RK, Zeng, J, Aziz, K, Salih, T, Gajula, RP, Chettiar, S, Gandhi, N, Wild, AT, Kumar, R, Herman, JM, Song, DY, DeWeese, TL |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Bentham Science Publishers
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3412203/ https://www.ncbi.nlm.nih.gov/pubmed/22292443 http://dx.doi.org/10.2174/156652412800792589 |
Ejemplares similares
-
Molecularly Targeted Agents as Radiosensitizers in Cancer Therapy—Focus on Prostate Cancer
por: Alcorn, Sara, et al.
Publicado: (2013) -
Concurrent versus Sequential Sorafenib Therapy in Combination with Radiation for Hepatocellular Carcinoma
por: Wild, Aaron T., et al.
Publicado: (2013) -
Confronting Racism in Radiation Oncology: Now Is the Time and Today Is the Day
por: DeWeese, Theodore L.
Publicado: (2020) -
End-of-radiation PSA as a novel prognostic factor in patients undergoing definitive radiation and androgen deprivation therapy for prostate cancer
por: Narang, Amol K., et al.
Publicado: (2017) -
Radiation Therapy in the Definitive Management of Oligometastatic Prostate Cancer: The Johns Hopkins Experience
por: Deek, Matthew P., et al.
Publicado: (2019)